A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

Pavel, M; Schuppan, D; Jost, L; Kerr, D; Harris, A; Jalava, T; Masson, E; Palacay-Radona, M; Koehne, C

Journal article

A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

Publication status:: Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Pavel, M., Schuppan, D., Jost, L., Kerr, D., Harris, A., Jalava, T., Masson, E., Palacay-Radona, M., & Koehne, C. (2016). A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients. EJC SUPPLEMENTS, 3(2), 427–427.

MLA Style

Pavel, M., et al. “A Phase I, Open-Label Study with Escalating Doses of Intravenous PTK787/ZK 222584, a Multi-VEGF Receptor Inhibitor, Followed by Multiple Oral Daily Dosing to Assess the Absolute Bioavailability of PTK787/ZK 222584 after Single and Multiple Doses in Advanced Cancer Patients.” EJC SUPPLEMENTS, vol. 3, no. 2, 2016, pp. 427–27.

Chicago Style

Pavel, M, D Schuppan, L Jost, D Kerr, A Harris, T Jalava, E Masson, M Palacay-Radona, and C Koehne. 2016. “A Phase I, Open-Label Study with Escalating Doses of Intravenous PTK787/ZK 222584, a Multi-VEGF Receptor Inhibitor, Followed by Multiple Oral Daily Dosing to Assess the Absolute Bioavailability of PTK787/ZK 222584 after Single and Multiple Doses in Advanced Cancer Patients.” EJC SUPPLEMENTS 3 (2): 427–27.
Tweet
Print